Douglas Hunt
Vermögen: 945 350 $ am 31.05.2026
Vermögen: 945 350 $ am 31.05.2026
Mr. Douglas Hunt is a Chief Regulatory Affairs Officer at Puma Biotechnology, Inc. Mr. Hunt was previously employed as a VP-Regulatory Affairs & Quality Assurance by ArmaGen, Inc., a Vice President-Global Regulatory Affairs by Baxter Healthcare Corp., and an Executive Director-Therapeutic Area by Amgen, Inc. He received his undergraduate degree from the University of Portsmouth.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
PUMA BIOTECHNOLOGY, INC. 0,26 % | 13.04.2026 | 131 848 ( 0,26 % ) | 945 350 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | General Counsel | 01.01.2018 |
| Unternehmen | Position | Ende |
|---|---|---|
ArmaGen, Inc.
ArmaGen, Inc. Pharmaceuticals: MajorHealth Technology Develops neurological therapies | General Counsel | 01.12.2017 |
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Develops, manufactures and distributes hospital supplies and medical technologies | General Counsel | 01.03.2015 |
| AMGEN INC. | Corporate Officer/Principal | 01.07.2008 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Develops, manufactures and distributes hospital supplies and medical technologies | Health Technology |
ArmaGen, Inc.
ArmaGen, Inc. Pharmaceuticals: MajorHealth Technology Develops neurological therapies | Health Technology |
University of Portsmouth
University of Portsmouth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Puma Biotechnology, Inc.
Puma Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen